This article will focus on the studies that consistently argue in favor of an interrelation between HCV and insulin resistance and will highlight the latest discoveries in this field.
ABSTRACT: Hepatitis C Virus (HCV) infection is one of the main causes of chronic liver disease worldwide.
Egypt has the highest prevalence of Hepatitis C Virus (HCV) in the world, estimated nationally at 14.7%.
A significant portion of the morbidity and mortality associated with HCV is a consequence of numerous HCV-associated comorbidities.
Type 2 diabetes and atherosclerosis, two known complications of the metabolic syndrome, are noteworthy, because HCV has been suggested to play a role in their pathogenesis.
7.3±4.0μg/ml; p=0.001; adjusted estimate 1.8, 1.7-2.9; p=0.001), and than in NAFLD patients (8.3±4.5μg/ml vs.
6.0±4.2μg/ml; p ABSTRACT: The hepatitis C virus (HCV) is a major cause of chronic hepatitis, cirrhosis and hepatocellular carcinoma worldwide.Some preliminary observations seem to suggest that indirect mechanisms involving extrahepatic organs might also play a role.The interaction between HCV and glucose metabolism has significant clinical consequences.We aimed to find more predictive markers those can help clinicians to choose the most effective treatment program for each patient.Assessment of HLA-DRB1, HLA-DQB1 genes by Sequence Specific Primer (SSP) PCR, interleukin-10 (IL-10) by ELISA technique and Serum HCV RNA load by Taq Man Real Time RT-PCR technology were done.ADIPOQ genotype was evaluated by Taqman assays, serum adiponectin measured by ELISA.